About Crescendo Biologics Ltd
Crescendo Biologics is building a pipeline of novel medicines based on its highly innovative V H antibody fragment platform through both in-house development and strategic partnerships. Crescendo's proprietary V H technology produces human heavy chain-only antibodies in the transgenic Crescendo Mouse providing a unique source of fully human V H fragments that have matured in vivo to have high affinity, stability and solubility. V H fragments are the smallest antibody fragments that retain binding affinity and specificity offering the potential to generate novel products with improved drug-like properties and able to address unmet medical needs.
Crescendo's technologies originated from discoveries by scientists at the Babraham Institute, Cambridge (UK). The company has raised funding totalling £7.7 million from an investment consortium led by Sofinnova Partners with Avlar BioVentures, Babraham Bioscience Technologies, and the Rainbow Seed Fund.